Skip to main content

Advertisement

SpringerLink
Log in

Oncologists greet Lumakras: the world’s first KRAS inhibitor

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A Publisher Correction to this article was published on 12 October 2021

This article has been updated

The milestone approval for Amgen’s drug Lumakras will galvanize targeted therapy efforts against Ras oncoproteins and provides a powerful new last line of defense for patients with lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

Author information

Authors and Affiliations

  1. Dublin, Ireland

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Oncologists greet Lumakras: the world’s first KRAS inhibitor. Nat Biotechnol 39, 1032–1034 (2021). https://doi.org/10.1038/s41587-021-01053-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-021-01053-9

  • Springer Nature America, Inc.

Search

Navigation